Cure8 research brief
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and non-responders and may guide future biomarker or therapeutic research.
Clinicians treating UC with biologics, researchers studying IBD biomarkers or treatment resistance, and patients on or considering anti‑TNF therapy who are interested in why some people do not respond.
This is a multi-cohort transcriptomic analysis (three infliximab-treated UC cohorts, n = 79) that prioritized cross-cohort, pathway-level signals over single-gene findings.
The authors derived a 68-gene consensus non-response signature that generalized in leave-one-dataset-out testing and remained directionally positive after adjusting for baseline inflammatory/remodeling proxies, though some attenuation occurred.
The study supports the idea that a pretreatment mucosal inflammatory/remodeling disease state is associated with short-term anti‑TNF non-response, and that the biology localizes to specific epithelial and myeloid/dendritic-cell states in single-cell references.
This work proposes a biologically coherent framework rather than a ready-to-use clinical predictor; the authors note overlap with baseline inflammatory burden and caution that the signature is not yet a deployable test.
This article reports an abstract-level transcriptomic analysis published in Frontiers in Genetics. The structured content depth is abstract; Cure8 did not review additional unpublished data.
The authors emphasize cross-cohort reproducibility but also report that the signature overlaps substantially with baseline inflammatory/remodeling burden and is not presented as a clinical diagnostic tool.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...
